Researchers at the Johns Hopkins Bloomberg School of Public Health conducted an analysis of worldwide use of Haemophilus influenza Type b vaccine (Hib) to determine what factors influenced a nation’s adoption of the vaccine. The study found that a nation’s eligibility for support from the Global Alliance for Vaccine and Immunization (GAVI) and whether a country’s neighbors used the vaccine were major influencing factors in addition to price of the vaccine. The findings appear in the March 16 edition of PLoS Medicine.
“This study is the first to measure how countries' decisions to adopt new vaccines are highly influenced by their neighbors' decisions,” said the study’s lead author, Jessica Shearer, MHS, a former research associate at the Bloomberg School of Public Health. “Countries seem to be engaging in an arms race to vaccinate -- decisions which will save millions of lives.”
For the study, the researcher analyzed data on Hib use from 147 countries from 1990 to 2007. Models were developed to account for a nation’s income and burden of Hib disease.
According to the study, the receipt of GAVI support sped up the time on decisions to use Hib by 63 percent. The presence of two or more neighboring countries using Hib accelerated adoption by 50 percent. An increase in price negatively affected the time it took a country to adopt Hib vaccine, which substantiated the findings of previous studies. Added Shearer, “While high vaccine prices hinder adoption, the absence of long-term, stable financing policies at the global level had an even more detrimental effect.”
The World Health Organization estimates 2.1 million people died worldwide in 2002 due to vaccine-preventable diseases. “GAVI has been hoping to accelerate the speed at which poor countries get access to life-saving vaccines. This study shows how successful these efforts have actually been,” said David Bishai, MD, PhD, MPH, senior author of the study and associate professor in the Bloomberg School’s departments of Population, Family and Reproductive Health and International Health.
Additional authors of “Accelerating Policy Decisions to Adopt Haemophilus influenza Type b Vaccine: A Global, Multivariable Analysis” are Meghan L. Stack, Marcie Richmond, Allyson P. Bear and Rana A. Hajjeh.
The research was funded by the Hib Initiative, which receives funding from the GAVI Alliance.
How Contaminated Is Your Stretcher? The Hidden Risks on Hospital Wheels
July 3rd 2025Despite routine disinfection, hospital surfaces, such as stretchers, remain reservoirs for harmful microbes, according to several recent studies. From high-touch areas to damaged mattresses and the effectiveness of antimicrobial coatings, researchers continue to uncover persistent risks in environmental hygiene, highlighting the critical need for innovative, continuous disinfection strategies in health care settings.
Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25
June 30th 2025Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.
A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides
June 26th 2025As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.